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1.1. Need for developing case definitions and guidelines for data
collection, analysis, and presentation for dysfunctional labor as an
adverse event following immunization
Vaccination during pregnancy is recommended for both mater-
nal and neonatal benefit against a number of potential infections.
The tetanus toxoid, reduced diphtheria toxoid and acellular pertus-
sis vaccine is now routine recommended for pregnant women in
each pregnancy not only for maternal benefit, but to confer passiveantibody transfer to the newborn until infant immunizations can
be given [1]. Influenza vaccinations are also strongly recommended
for any pregnant woman, or women who might become pregnant
during influenza seasons [2]. The safety of both these vaccinations
has been well established. Efforts to develop new vaccinations for
use during pregnancy represent a new opportunity to prevent
common maternal and neonatal infections with severe morbidity
and mortality. There is growing interest and research around
maternal immunization against both Group B streptococcus
(GBS) and Respiratory syncytial virus (RSV) as a public health strat-
egy to prevent neonatal and infant infections worldwide [3,4].
Establishing the safety profile of any new vaccination requires
careful surveillance of potential adverse effects and consistent
terminology and definitions across context and time. The World
Health Organization (WHO) defines an ‘adverse event following
immunization’ (AEFI) as ‘‘any untoward medical occurrence
which follows immunization and, which does not necessarily
Table 1
Summary of professional guidelines.
Professional
Organization
Year
Published
First Stage Second Stage
Nulliparous Multiparous Nulliparous Multiparous
NICE [29] 2014 Normal: 8–18 h Normal: 5–12 h Birth expected within
3 h of start of active
second stage
Birth expected
within 2 h of start
of active stage
Suspected delay: <2 cm in 4 h, with delay
confirmed with progress of less than 1 cm
h later
Delay: <2 cm in 4 h OR slowing in progress
of labor
Delay: 2 or more hours Delay: 1 or more
hours
ACOG/SMFM
[11]
2014 Normal < 20 h Normal < 14 h No maximum time
frame
No maximum time
frame
Arrest: 6 cm dilation and 4 h or more of
adequate contractions or 6 h or more of
inadequate contractions
Arrest: 6 cm dilation and 4 h or more of
adequate contractions or 6 h or more of
inadequate contractions
Permit at least Permit at least
3 h of pushing 2 h of pushing
RANZCOG [30] 2014 Prolonged if: <1 cm/h in active phase Prolonged if: <1 cm/h in active phase >2 h >1 h
WHO [31] 2014 <0.5 cm to 1 cm/h during the active phase <0.5 cm to 1 cm/h during the active phase N/A N/A
SOGC [32] 1995 <0.5 cm/h over a 4 h period <0.5 cm/h over a 4 h period 2 h if no regional
anesthesia
N/A
FIGO [33] 2012 N/A N/A No more than 3 h of
active pushing
No more than 2 h of
active pushing
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adverse event may be an unfavorable or unintended sign, an
abnormal laboratory finding, a symptom or disease” [5]. Recog-
nizing that vaccination is often temporally related to many
events, abnormal findings or diseases, causality assessment
between an AEFI and vaccination requires further rigorous
assessment and study. Monitoring of a broad array of events,
including those without established or suspected links to vaccine
can therefore provide the initial basis for data with which such
causality can be proven or disproven.
Dysfunctional labor is relatively common occurrence during
the intrapartum stage of pregnancy. Incidence estimates vary
due to differences in definitions, but approximately 20% of labors
are thought to be affected by this condition [6]. Though there
are no reported links between dysfunctional labor and immu-
nization, the measurement of this potential complication in asso-
ciation with vaccination is important to establish vaccine safety.
Despite being relatively common, there is a lack of consensus on
the criteria for the diagnosis of dysfunctional labor. Guidelines
from professional obstetric societies differ in both the criteria
used to define this process and when intervention should occur
(Table 1). The Brighton Collaboration has been developing stan-
dardized definitions for use in vaccine trials since 2001 [7]. To
further consistent terminology and definitions of outcomes and
adverse events typically reported in vaccine trials, specifically
for maternal immunization, standardized definitions of common
obstetric outcomes are needed. The goal of this working group
was therefore to provide a case definition for this term to facil-
itate surveillance and case ascertainment in vaccine trials.
Labor is typically divided into three stages. The first stage of
labor marks the onset of labor until full dilation of the cervix;
the second stage, full dilation until delivery of the fetus, and the
third, delivery of the placenta. In the 1950s, Friedman first
described the first stage dividing this into latent and active phases
of labor [8,9]. His work first demonstrated the broad range of labor
duration experienced by women and until recently provided the
basis for defining normal progress and length of labor limits of nor-
mal labor duration. Recent evidence, however, from a larger more
diverse population of women have challenged these historical
durations [10].
Dysfunctional or prolonged labor refers to prolongation in the
duration of labor, typically in the first stage of labor. Diagnosis of
delay in labor is dependent on careful monitoring of uterine con-
traction intensity, duration and frequency, cervical dilation and
descent of the fetus through the pelvis. Dysfunctional labor canbe an important contributor to maternal and perinatal mortality
and morbidity if it remains unrecognized and untreated when
needed. On the other hand, pre-emptive diagnosis of dysfunctional
labor may lead to unnecessary interventions. Labor dysfunction is a
leading indication for primary caesarean section and there is con-
cern, that an over diagnosis may be a contributor to high and rising
caesarean section rates [11].
The pathophysiology of dysfunctional labor is multifactorial
and complex and yet to be fully elucidated. Often, the exact eti-
ology of dysfunctional labor is unknown. Broadly, etiology can
be categorized into uterine contractile dysfunctions and abnor-
malities in the cephalopelvic ratio (i.e. the relation of the fetal
size, presentation and position to the maternal pelvis). Both
these causes can be influenced by a number of genetic and envi-
ronmental factors including but not limited to maternal and ges-
tational age, pre-pregnancy body mass index, pregnancy weight
gain, physical activity, medical co-morbidities, parity, and
obstetric complications (pre-eclampsia, premature rupture of
membranes, chorio-amnionitis, placental abruption) [12–15].
1.2. Methods for the development of the case definition and guidelines
for data collection, analysis, and presentation for dysfunctional labor
as an adverse events following immunization
Following the process described in the overview paper [16] as
well as on the Brighton Collaboration Website http://www.
brightoncollaboration.org/internet/en/index/process.html, the
Brighton Collaboration Dysfunctional Labor Working Group was
formed in 2015 and included members of clinical, academic, public
health and industry background. The composition of the working
and reference group as well as results of the web-based survey
completed by the reference group with subsequent discussions in
the working group can be viewed at: http://www.brightoncollabo-
ration.org/internet/en/index/working_groups.html.
To guide the decision-making for the case definition and guide-
lines, a literature search for publications in any language was per-
formed using Medline, Embase and the Cochrane Libraries,
including the terms dysfunctional, prolonged, delayed, obstructed,
abnormal, augmented labor, arrest of dilation, labor dystocia AND
‘vaccination’ or ‘vaccine’ or ‘immunization’ OR ‘immunize’ OR
‘inoculation’. The search resulted in the identification of 172 refer-
ences. All abstracts were screened for possible reports of dysfunc-
tional labor following immunization. Two full text articles with
potentially relevant material were reviewed in more detail, in
order to identify studies using case definitions or, in their absence,
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review resulted in no articles providing case reports or case defini-
tions of dysfunctional labor following immunization.
To further guide decision-making process, guidelines from
major professional obstetric societies were reviewed and defini-
tions of dysfunctional or prolonged labor summarized and pro-
vided to members of the working group for review (Table 1).
1.3. Rationale for selected decisions about the case definition of
dysfunctional labor as an adverse event following immunization
Our focus throughout this process is to provide criteria for diag-
nostic certainty for the purpose of case definition rather than for
the identification of time frames for intervention or management
changes. This is a marked difference from the definitions provided
in most guidelines where a timeframe or criteria are used to sug-
gest when intervention and management changes should occur.
Thus, a case meeting the definitions provided may or may not war-
rant intervention, however it is not within the purview of this
working group to provide such recommendations.
We recommend criteria used in case ascertainment as defined
below are restricted to term singleton pregnancies, i.e. at or after
37 completed weeks and before 42 weeks of pregnancy. The patho-
physiology and course of labor in preterm, previable pregnancies
or postdate pregnancies was felt to be sufficiently different that
separate terminology and case definitions should apply. Both pre-
term labor and pregnancy loss have been separately defined by
working groups though the Brighton collaboration [19,20]. Despite
similarities between labor in multiple vs. singleton gestations the
working group felt the interaction between vaccination in a these
different gestations may be different and thus warrant a separate
consideration.
Definitions were formed separately for both the first stage and
second stage of labor. Within the first stage we choose to focus on
a definition of dysfunction once the established or active labor is
reached. The definitions, therefore do not address potential dys-
function or protraction of the latent phase in the first stage of
labor. Established labor describes the onset of active labor, (regu-
lar contractions and a cervical dilation of 4 centimeter (cm)). This
is distinct from the active phase of the first stage as described by
Zhang et al. where there is acceleration in the rate of dilation at
6 cm. This stage of cervical dilation has since been used by United
States professional societies as the basis for recommendations on
a point before which unnecessary intervention should be avoided,
rather than as a definition of established labor [21,10]. Estab-
lished labor was also chosen as the starting time point as it
includes all labors once they are established, regardless of
whether they were initially induced or spontaneous. The require-
ment for regular contractions and cervical dilation of at least 4 cm
would mean that an induced labor that begins with foley catheter
cervical ripening and achieves a mechanical dilation of 4 cm, but
without regular contractions is not considered in established
labor. Similarly a multiparous woman with a cervix dilated to
4 cm but without any contractions would not be considered in
established labor.
We chose not to include the use of regional analgesia as a sep-
arate category within our definitions for both first and second
stages of labor. We recognize that during routine clinical practice,
the diagnosis of dysfunctional labor and potential subsequent
intervention is often adjusted in the presence of regional analgesia.
Current evidence suggests no impact of regional anesthesia on the
first stage [22]. We recognize literature that shows that the second
stage is longer in women with regional anesthesia [22], however
for the purposes of case definition the working group considered
regional analgesia a risk factor for a prolonged second stage rather
than warranting separate categorization. As noted above, the scopeof these definitions are for case ascertainment alone and not to
prescribe or prevent intervention. Thus by excluding regional
anesthesia as an influence on the case definition we do not mean
to suggest any change in management decisions that might occur
in women who do undergo regional anesthesia.
In formulating a case definition that reflects diagnostic certainty
we weighed specificity versus sensitivity. After reaching consen-
sus, only two levels of definition were formed, both of which relate
to diagnostic certainty around case definition, rather than clinical
severity of a case. To make the diagnosis of dysfunctional labor,
an examiner capable of reliably assessing uterine contractions,
amniotic membrane status (intact vs. ruptured), cervical dilation,
fetal station and a measure of time is required. The case definition
has been formulated such that the level one definition is highly
specific for the condition. As maximum specificity normally
implies a loss of sensitivity, one additional diagnostic level has
been included in the definition, offering a stepwise increase of sen-
sitivity from level one to level two, while retaining an acceptable
level of specificity at all levels. In this way it is hoped that all pos-
sible cases of dysfunctional labor can be captured. In the first stage
of labor, certainty around ruptured membranes distinguishes
between a level one and level two level of certainty. This second
level of diagnostic certainty recognizes circumstances where the
timing or certainty of rupture of membranes is unknown to the
woman or her provider or is not documented in the medical record.
In the second stage of labor, diagnostic certainty in level one and
two are distinguished by certainty around the onset of active
maternal effort i.e. pushing or visible baby after full dilation (cervix
is reported at 10 cm or no longer felt around the presenting part).
This allows for variations in practice where women are allowed
passive descent of the fetal head after full dilation or in cases
where the onset of active pushing after full dilation is not recorded.
In both stages of labor, the working group determined a third level
of definition would be not be specific enough to reliably measure
cases of dysfunctional labor, therefore a third level of diagnostic
certainty was not included.
1.3.1. Influence of treatment on fulfillment of case definition
The Working Group decided against using ‘‘treatment” or
‘‘treatment response” towards fulfillment of dysfunctional labor
case definition except in the second stage of labor. No distinction
is made between spontaneous, augmented or induced labors,
though recognizing, that induction may represent a risk factor for
labor dysfunction. Similarly in the second stage of labor, no distinc-
tion is made for labors in which women receive regional anesthe-
sia, though as noted above, it is recognized that this might
represent a risk factor for prolonged second stage. We designed
both level one and two definitions to be broad enough to include
cases presenting differently due to appropriate and early treatment
initiation.
An exception is made for intervention for delivery in the second
stage of labor, either by operative vaginal delivery or caesarean
delivery for the indication of failure to progress or arrest of des-
cent. This exception was made as it was felt practice patterns exist
where early intervention is performed in the second stage and
exclusion of these cases could result in underreporting of dysfunc-
tional labor.
1.3.2. Timing post immunization
Specific time frames for the onset of symptoms following immu-
nization are not included in this definition. Due to the lack of a
reported link between dysfunctional labor and immunization, and
no postulated biological plausibility for a link, we felt a restrictive
time interval from immunization to onset of dysfunctional labor
should not be an integral part of such a definition. Furthermore,
labor often occurs outside the controlled setting of a clinical trial
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timeline of the event, particularly in less developed or rural
settings. In order to avoid selecting against such cases, the Brighton
Collaboration case definition avoids setting arbitrary time frames.
Therefore, we recommend that details of this interval should be
assessed and reported as described in the data collection guidelines.
1.4. Guidelines for data collection, analysis and presentation
As mentioned in the overview paper, the case definition is
accompanied by guidelines which are structured according to the
steps of conducting a clinical trial, i.e. data collection, analysis and
presentation. Neither case definition nor guidelines are intended
to guide or establish criteria for management of ill infants, children,
or adults. Both were developed to improve data comparability.
1.5. Periodic review
Similar to all Brighton Collaboration case definitions and guide-
lines, review of the definition with its guidelines is planned on a
regular basis (i.e. every three to five years) or more often if needed.
2. Case definition of dysfunctional labor
2.1. First stage of labor
For both levels of diagnostic certainty, the woman is in estab-
lished labor defined by regular contractions and cervical dilation
of at least 4 cm.
Level 1 of diagnostic certainty
Progress of less than 0.5 cm cervical dilation per hour, for at
least 4 h,2 in women in established labor (i.e. have regular contrac-
tions and cervical dilation of at least 4 cm) and with confirmed rup-
tured membranes.3
Level 2 of diagnostic certainty
Progress of less than 0.5 cm cervical dilation per hour in
women, for at least 4 h, with established labor (i.e. that is, regular
contractions and cervical dilation of at least 4 cm) without cer-
tainty of ruptured membranes.
2.2. Second stage of labor
Level 1 of diagnostic certainty
Nulliparous women:
Full dilation4 of the cervix
AND
onset of the active stage (active maternal effort (i.e. pushing) OR
visible baby)
AND
greater than 2 h of pushing2 ‘‘Fo
Thus a
subsequ
labor. It
3 Con
exclude
contrac
woman
4 Full
around
5 Inst
6 Dys
to indicOR use of instrument delivery for the indication of
dystocia5,6r at least 4 h” was added to ensure adequate time allowed for progression.
case where progression is less than 0.5 cm in the first hour, but then
ently speeds up would not meet the criteria for delayed or dysfunctional
must be less than 0.5 cm/h averaged over 4 h.
firmed rupture of membranes is added to a level 1 of diagnostic certainty to
those women with advanced cervical exams who may have intermittent
tions but may not be in established labor. For example, the multiparous
with an advanced cervical exam.
dilation of the cervix is described as 10 cm dilated, or no palpable cervix
the presenting part of the fetus.
rument delivery refers to delivery by forceps or vacuum/ventouse.
tocia indications include arrest of descent and failure to progress as opposed
ations for fetal well-being.OR caesarean delivery for the indication of dystocia (see
footnote 6)
Multiparous women:
Full dilation of the cervix
AND
onset of the active stage (active maternal effort (i.e. pushing) OR
visible baby)
AND
greater than 1 h of pushingOR use of instrument delivery for the indication of dystocia
(see footnotes 5 and 6)
OR caesarean delivery for the indication of dystocia (see
footnote 6)
Level 2 of diagnostic certainty
Nulliparous women
Full dilation of the cervix in any phase of the second stage
AND
no delivery within 3 h of full dilationOR use of instrument delivery for the indication of dystocia
(see footnotes 5 and 6)
OR caesarean delivery for the indication of dystocia (see
footnote 5)
Multiparous women
Full dilation of the cervix in any phase of the second stage
AND
no delivery within 3 h of full dilationOR use of instrument delivery for the indication of dystocia
(see footnotes 5 and 6)
OR caesarean delivery for the indication of dystocia (see
footnote 5)
3. Guidelines for data collection, analysis and presentation of
dysfunctional labor
It was the consensus of the Brighton Collaboration Dysfunctional
Labor Working Group to recommend the following guidelines to
enable meaningful and standardized collection, analysis, and pre-
sentation of information about dysfunctional labor. However,
implementation of all guidelines might not be possible in all set-
tings. The availability of information may vary depending upon
resources, geographical region, and whether the source of informa-
tion is a prospective clinical trial, a post-marketing surveillance or
epidemiological study, or an individual report of dysfunctional
labor. Also, as explained in more detail in the overview paper in
this volume, these guidelines have been developed by this working
group for guidance only, and are not to be considered a mandatory
requirement for data collection, analysis, or presentation.
3.1. Data collection
These guidelines represent a desirable standard for the collec-
tion of data on availability following immunization to allow for
comparability of data, and are recommended as an addition to
data collected for the specific study question and setting. The
guidelines are not intended to guide the primary reporting of
dysfunctional labor to a surveillance system or study monitor.
Investigators developing a data collection tool based on these
data collection guidelines also need to refer to the criteria in
the case definition, which are not repeated in these guidelines.
Guidelines numbers below have been developed to address data
elements for the collection of adverse event information as
specified in general drug safety guidelines by the International
Conference on Harmonization of Technical Requirements for Regis-
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reporting of drug adverse events by the Council for International
Organizations of Medical Sciences [24] and formulated by Jones
et al. [25]. These data elements include an identifiable reporter
and patient, one or more prior immunizations, and a detailed
description of the adverse event, in this case, of dysfunctional labor
following immunization. The additional guidelines have been
developed as guidance for the collection of additional information
to allow for a more comprehensive understanding of dysfunctional
labor following immunization.
3.1.1. Source of information/reporter
For all cases and/or all study participants, as appropriate, the
following information should be recorded:
(1) Date of report.
(2) Name and contact information of person reporting7 and/or
diagnosing the dysfunctional labor as specified by country-
specific data protection law.
(3) Name and contact information of the investigator responsi-
ble for the subject, as applicable.
(4) Relation to the patient (e.g. Immunizer [clinician, nurse],
family member [indicate relationship], other).
3.1.2. Vaccine/Control
3.1.2.1. Demographics. For all cases and/or all study participants, as
appropriate, the following information should be recorded:
(5) Case/study participant identifiers (e.g. first name initial fol-
lowed by last name initial) or code (or in accordance with
country-specific data protection laws).
(6) Date of birth, age, and sex.
(7) For infants born to study participants: Gestational age and
birth weight.3.1.2.2. Clinical and immunization history. For all cases and/or all
study participants, as appropriate, the following information
should be recorded:
(8) Past medical history, including hospitalizations, underlying
diseases/disorders, pre-immunization signs and symptoms
including identification of indicators for, or the absence of,
a history of allergy to vaccines, vaccine components or med-
ications; food allergy; allergic rhinitis; eczema; asthma.
(9) Any medication history (other than treatment for the event
described) prior to, during, and after immunization includ-
ing prescription and non-prescription medication as well
as medication or treatment with long half-life or long-term
effect (e.g. immunoglobulins, blood transfusion and
immunosuppressants).
(10) Immunization history (i.e. previous immunizations and any
adverse event following immunization (AEFI8)), in particular
occurrence of an adverse event after a previous immunization.
3.1.3. Details of the immunization
For all cases and/or all study participants, as appropriate, the
following information should be recorded:7 If the reporting centre is different from the vaccinating centre, appropriate and
timely communication of the adverse event should occur.
8 An AEFI is defined as serious by international standards if it meets one or more of
the following criteria: (1) it results in death, (2) is life-threatening, (3) it requires
inpatient hospitalization or results in prolongation of existing hospitalization, (4)
results in persistent or significant disability/incapacity, (5) is a congenital anomaly/
birth defect, (6) is a medically important event or reaction.(11) Date and time of immunization(s).
(12) Description of vaccine(s) (name of vaccine, manufacturer, lot
number, dose (e.g. 0.25 mL, 0.5 mL, etc.) and number of dose
if part of a series of immunizations against the same disease).
(13) The anatomical sites (including left or right side) of all
immunizations (e.g. vaccine A in proximal left lateral thigh,
vaccine B in left deltoid).
(14) Route and method of administration (e.g. intramuscular,
intradermal, subcutaneous, and needle-free (including type
and size), other injection devices).
(15) Needle length and gauge.
3.1.4. The adverse event
(16) For all cases at any level of diagnostic certainty and for
reported events with insufficient evidence, the criteria ful-
filled to meet the case definition should be recorded.
Specifically document:
(17) Clinical description of signs and symptoms of dysfunctional
labor and if there was medical confirmation of the event (i.e.
patient seen by physician).
(18) Date/time of onset of established labor,9 date/time of diagno-
sis of dysfunctional labor and final outcome including mode of
delivery.10
(19) Time interval since immunization.
(20) Concurrent signs, symptoms, and diseases.
(21) Measurement/testing:9 The
dysfunc
retrospe
10 Exa
therape Values and units of routinely measured parameters (e.g.
temperature, blood pressure) – in particular those indi-
cating the severity of the event.
 Method of measurement (e.g. type of thermometer, oral
or other route, duration of measurement, etc.).
 Results of laboratory examinations, surgical and/or
pathological findings and diagnoses if present.
 Include documentation of time and findings for cervical
exam, onset of established labor, time of initiation and
duration of regional analgesia if any, full dilation, onset
of maternal pushing in the second stage, and time of
delivery.(22) Treatment or intervention given for dysfunctional labor,
especially if medication dosing, if procedure – type of
procedure.
(23) Outcome(see footnote 10) at last observation.
(24) Exposures other than the immunization 24 h before and
after immunization (e.g. food, environmental) considered
potentially relevant to the reported event.
3.1.5. Miscellaneous/general
(25) The duration of surveillance for dysfunctional labor should
be predefined based on
 Biologic characteristics of the vaccine e.g. live attenuated
versus inactivated component vaccines.
 Biologic characteristics of the vaccine-targeted disease.
 Biologic characteristics of dysfunctional labor including
patterns identified in previous trials (e.g. early-phase
trials).
 Biologic characteristics of the vaccinee (e.g. nutrition,
underlying disease like immunodepressing illness).date and/or time of onset is defined as the time post immunization, when
tional labor is diagnosed. This may only be possible to determine in
ct.
mple recovery to pre-immunization health status, spontaneous resolution,
utic intervention, persistence of the event, sequelae, death.
Interval⁄ Number
<24 h after immunization
24 h to <72 h after immunization
72 h to <7 days after immunization
7 days to <30 days after immunization
More than 30 days
TOTAL
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period should be predefined likewise. It should aim to con-
tinue to resolution of the event, which in this case ascertain-
ment would be after delivery is completed.
(27) Methods of data collection should be consistent within and
between study groups, if applicable.
(28) Follow-up of cases should attempt to verify and complete
the information collected as outlined in data collection
guidelines 1–24.
(29) Investigators of patients with dysfunctional labor should
provide guidance to reporters to optimize the quality and
completeness of information provided.
(30) Reports of dysfunctional labor should be collected through-
out the study period regardless of the time elapsed between
immunization and the adverse event. If this is not feasible
due to the study design, the study periods during which
safety data are being collected should be clearly defined.
3.2. Data analysis
The following guidelines represent a desirable standard for
analysis of data on dysfunctional labor to allow for comparability
of data, and are recommended as an addition to data analyzed
for the specific study question and setting.
(31) Reported events should be classified in one of the following
five categories including the three levels of diagnostic cer-
tainty. Events that meet the case definition should be clas-
sified according to the levels of diagnostic certainty as
specified in the case definition. Events that do not meet
the case definition should be classified in the additional
categories for analysis.
Event classification in 5 categories11
Event meets case definition
(1) Level 1: Criteria as specified in the on dysfunctional labor case
definition
(2) Level 2: Criteria as specified in the on dysfunctional labor case
definition
Event does not meet case definition
Additional categories for analysis
(3) Reported dysfunctional labor with insufficient evidence to
meet the case definition.12
(4) Not a case of dysfunctional labor.13
(32) The interval between immunization and reported dysfunc-
tional labor could be defined as the date/time of immu-
nization to the date/time of onset (see footnote 9) of the
first symptoms and/or signs consistent with the definition.11 To determine the appropriate category, the user should first establish, whether a
reported event meets the criteria for the lowest applicable level of diagnostic
certainty, e.g. Level three. If the lowest applicable level of diagnostic certainty of the
definition is met, and there is evidence that the criteria of the next higher level of
diagnostic certainty are met, the event should be classified in the next category. This
approach should be continued until the highest level of diagnostic certainty for a
given event could be determined. If the lowest level of the case definition is not met, it
should be ruled out that any of the higher levels of diagnostic certainty are met and
the event should be classified in additional categories four or five.
12 If the evidence available for an event is insufficient because information is
missing, such an event should be categorized as ‘‘Reported dysfunctional labor with
insufficient evidence to meet the case definition”.
13 An event does not meet the case definition if investigation reveals a negative
finding of a necessary criterion (necessary condition) for diagnosis. Such an event
should be rejected and classified as ‘‘Not a case of dysfunctional labor”.If few cases are reported, the concrete time course could
be analyzed for each; for a large number of cases, data
can be analyzed in the following increments:
Subjects with dysfunctional labor by Interval to Presentation(33) The duration of a possible dysfunctional labor could be ana-
lyzed as the interval between the date/time of the first signs
consistent with the definition and the delivery of the fetus/
es14 (see footnote 10). Whatever start and ending are used,
they should be used consistently within and across study
groups.
(34) The distribution of data (as numerator and denominator
data) could be analyzed in predefined increments (e.g. mea-
sured values, times), where applicable. Increments specified
above should be used. When only a small number of cases
are presented, the respective values or time course can be
presented individually.
(35) Data on dysfunctional labor obtained from subjects receiv-
ing a vaccine should be compared with those obtained from
an appropriately selected and documented control group(s)
to assess background rates of hypersensitivity in non-
exposed populations, and should be analyzed by study arm
and dose where possible, e.g. in prospective clinical trials.
Sample size to evaluate exposed versus non-exposed popu-
lations should be calculated using background rates of dys-
functional labor in the population to be studied.
3.3. Data presentation
These guidelines represent a desirable standard for the presen-
tation and publication of data on dysfunctional labor following
immunization to allow for comparability of data, and are recom-
mended as an addition to data presented for the specific study
question and setting. Additionally, it is recommended to refer to
existing general guidelines for the presentation and publication
of randomized controlled trials, systematic reviews, and meta-
analyses of observational studies in epidemiology (e.g. statements
of Consolidated Standards of Reporting Trials (CONSORT), of
Improving the quality of reports of meta-analyses of randomized
controlled trials (QUORUM), and of Meta-analysis Of Observational
Studies in Epidemiology (MOOSE), respectively) [26–28].
(36) All reported events of on dysfunctional labor should be pre-
sented according to the categories listed in guideline 32.
(37) Data on possible on dysfunctional labor events should be
presented in accordance with data collection guidelines
1–24 and data analysis guidelines 31–35.
(38) Terms to describe on dysfunctional labor such as ‘‘low-
grade”, ‘‘mild”, ‘‘moderate”, ‘‘high”, ‘‘severe” or ‘‘significant”
are highly subjective, prone to wide interpretation, and
should be avoided.14 The end of an episode is defined as the time the event no longer meets the case
definition at the lowest level of the definition.
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(n/N) (and not only in percentages), if available.
Although immunization safety surveillance systems denomina-
tor data are usually not readily available, attempts should be
made to identify approximate denominators. The source of
the denominator data should be reported and calculations of
estimates be described (e.g. manufacturer data like total doses
distributed, reporting through Ministry of Health, coverage/
population based data, etc.).
(40) The incidence of cases in the study population should be
presented and clearly identified as such in the text.
(41) If the distribution of data is skewed, median and range are
usually the more appropriate statistical descriptors than a
mean. However, the mean and standard deviation should
also be provided.
(42) Any publication of data on dysfunctional labor should
include a detailed description of the methods used for data
collection and analysis as possible. It is essential to specify:15 The
for dysf
16 The
met the
17 Use
respect
ration.o The study design.
 The method, frequency and duration of monitoring for on
dysfunctional labor.
 The trial profile, indicating participant flow during a
study including drop-outs and withdrawals to indicate
the size and nature of the respective groups under
investigation.
 The type of surveillance (e.g. passive or active
surveillance).
 The characteristics of the surveillance system (e.g. popu-
lation served, mode of report solicitation).
 The search strategy in surveillance databases.
 Comparison group(s), if used for analysis.
 The instrument of data collection (e.g. standardized ques-
tionnaire, diary card, report form).
 Whether the day of immunization was considered ‘‘day
one” or ‘‘day zero” in the analysis.
 Whether the date of onset (see footnote 9) and/or the
date of first observation15 and/or the date of diagnosis16
was used for analysis.
 Use of this case definition for on dysfunctional labor, in
the abstract or methods section of a publication.17Disclaimer
The findings, opinions and assertions contained in this consen-
sus document are those of the individual scientific professional
members of the working group. They do not necessarily represent
the official positions of each participant’s organization (e.g. govern-
ment, university, or corporation). Specifically, the findings and con-
clusions in this paper are those of the authors and do not
necessarily represent the views of their respective institutions.
Acknowledgements
SK was supported by the NIHR Collaborations for Leadership in
Applied Health Research and Care West Midlands initiative. The
views expressed are those of the author(s) and not necessarily
those of the NHS, the NIHR or the Department of Health. The
authors are grateful for the support and helpful comments pro-date and/or time of first observation of the first sign or symptom indicative
unctional labor can be used if date/time of onset is not known.
date of diagnosis of an episode is the day post immunization when the event
case definition at any level.
of this document should preferably be referenced by referring to the
ive link on the Brighton Collaboration website (http://www.brightoncollabo-
rg).vided by the Brighton Collaboration and the reference group
(see https://brightoncollaboration.org/public/what-we-do/setting-
standards/case-definitions/groups.html for reviewers), as well as
other experts consulted as part of the process. The authors are also
grateful to Jan Bonhoeffer, and Jorgen Bauwens of the Brighton Col-
laboration Secretariat for final revisions of the final document.
Finally, we would like to acknowledge the Global Alignment of
Immunization Safety Assessment in Pregnancy (GAIA) project,
funded by the Bill and Melinda Gates Foundation.Appendix A. Supplementary material
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.vaccine.2017.01.
050.
References
[1] Updated recommendations for use of tetanus toxoid, reduced diphtheria
toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons
who have or anticipate having close contact with an infant aged <12 months –
Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb
Mortal Wkly Rep 2011;60(41):1424–6.
[2] Grohskopf LA et al. Prevention and control of seasonal influenza with vaccines:
recommendations of the Advisory Committee on Immunization Practices
(ACIP) – United States, 2014–15 influenza season. MMWR Morb Mortal Wkly
Rep 2014;63(32):691–7.
[3] Munoz FM, Ferrieri P. Group B Streptococcus vaccination in pregnancy:
moving toward a global maternal immunization program. Vaccine 2013;31:
D46–51.
[4] Munoz FM. Respiratory syncytial virus in infants: is maternal vaccination a
realistic strategy? Curr Opin Infect Dis 2015;28(3):221–4.
[5] World Health Organization. Causality assessment of an adverse event
following immunization (AEFI): user manual for the revised WHO
classification. Geneva: World Health Organization; 2013.
[6] Zhu BP et al. Labor dystocia and its association with interpregnancy interval.
Am J Obstet Gynecol 2006;195(1):121–8.
[7] Brighton Collaboration. Brighton Collaboration – Our Story. Available from:
<https://brightoncollaboration.org/public/who-we-are/our-story.html> [cited
2016 June 29th].
[8] Friedman EA. The graphic analysis of labor. Am J Obstet Gynecol 1954;68
(6):1568–75.
[9] Friedman EA. Primigravid labor: a graphicostatistical analysis. Obstet Gynecol
1955;6(6):567–89.
[10] Zhang J et al. Contemporary patterns of spontaneous labor with normal
neonatal outcomes. Obstet Gynecol 2010;116(6):1281.
[11] Caughey AB et al. Safe prevention of the primary cesarean delivery. Am J
Obstet Gynecol 2014;210(3):179–93.
[12] Sheiner E et al. Risk factors and outcome of failure to progress during the first
stage of labor: a population-based study. Acta Obstet Gynecol Scand 2002;81
(3):222–6.
[13] Selin L, Wallin G, Berg M. Dystocia in labour–risk factors, management and
outcome: a retrospective observational study in a Swedish setting. Acta Obstet
Gynecol Scand 2008;87(2):216–21.
[14] Kjaergaard H et al. Risk indicators for dystocia in low-risk nulliparous women:
a study on lifestyle and anthropometrical factors. J Obstet Gynaecol 2010;30
(1):25–9.
[15] Kjærgaard H et al. Obstetric risk indicators for labour dystocia in nulliparous
women: a multi-centre cohort study. BMC Preg Childbirth 2008;8(1):1.
[16] Kohl KS et al. The development of standardized case definitions and guidelines
for adverse events following immunization. Vaccine 2007;25(31):5671–4.
[17] Orenstein LA et al. Background rates of adverse pregnancy outcomes for
assessing the safety of maternal vaccine trials in sub-Saharan Africa. PLoS ONE
2012;7(10):e46638.
[18] Salam RA et al. Impact of Haemophilus influenzae type B (Hib) and viral
influenza vaccinations in pregnancy for improving maternal, neonatal and
infant health outcomes. Cochrane Database Syst Rev 2015(6):CD009982.
[19] Harrison MS et al. Pathways to preterm birth: case definition and guidelines
for data collection, analysis, and presentation of immunization safety data.
Vaccine 2016.
[20] Da Silva FT et al. Stillbirth: case definition and guidelines for data collection,
analysis, and presentation of maternal immunization safety data. Vaccine
2016.
[21] Spong CY et al. Preventing the first cesarean delivery: summary of a joint
Eunice Kennedy Shriver National Institute of Child Health and Human
Development, Society for Maternal-Fetal Medicine, and American College of
Obstetricians and Gynecologists workshop. Obstet Gynecol 2012;120
(5):1181–93.
[22] Anim-Somuah M, Smyth R, Jones L. Epidural versus non-epidural or no
analgesia in labour. Cochrane Database Syst Rev 2011:12.
A.A. Boatin et al. / Vaccine 35 (2017) 6538–6545 6545[23] International Conference on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use (ICH). Guidelines for clinical
safety assessment (E2a-e) [accessed at: <http://www.ich.org/>].
[24] Council for International Organizations of Medical Sciences (CIOMS).
Reporting form for international reporting of adverse drug reactions
[accessed at <http://www.cioms.ch/>].
[25] Jones CE et al. Guideline for collection, analysis and presentation of safety data
in clinical trials of vaccines in pregnant women. Vaccine 2016.
[26] Moher D et al. Improving the quality of reports of meta-analyses of
randomised controlled trials: the QUOROM statement. Quality of reporting
of meta-analyses. Lancet 1999;354(9193):1896–900.
[27] Moher D et al. The CONSORT statement: revised recommendations for
improving the quality of reports of parallel-group randomized trials. JAMA
2001;285(15):1987–91.
[28] Stroup DF et al. Meta-analysis of observational studies in epidemiology: a
proposal for reporting. Meta-analysis Of Observational Studies in
Epidemiology (MOOSE) group. JAMA 2000;283(15):2008–12.[29] National Collaborating Centre for Women’s and Children’s Health. Intrapartm
care: care of health women and their babies during childbirth. In: Clinical
Guidline 190. National Institute for Health and Care Excellence; 2014.
[30] The Royal Australian and New Zealand College of Obstetricians and
Gynaecologist. Provision of routine intrapartum care in the abscence of
pregnancy complications. RANZCOG; 2014.
[31] World Health Organization. Recommendations for augmentation of
labout. Geneva: World Health Organization; 2014.
[32] Society of Obstetricians and Gynaecologists of Canada, Dystocia. In: Clinical
Practice Guidelines for Obstetrics; 1995.
[33] Motherhood FS, Newborn Health C. Management of the second stage of labor.
Int J Gynaecol Obstet 2012;119(2):111–6.
